REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Safety profile for DRd vs Rd.1


REVLIMID® + dexamethasone + daratumumab Safety Data
  • Infusion-related reactions determined by investigators.
Full Adverse Reactions Table
  • Grade 3 or 4 hematology laboratory abnormalities in the DRd arm compared to the Rd arm included: neutropenia (DRd 56% vs Rd 39%), lymphopenia (DRd 52% vs Rd 42%), leukopenia (DRd 35% vs Rd 24%), anemia (DRd 13% vs Rd 24%), and thrombocytopenia (DRd 9% vs Rd 11%)
  • Serious adverse reactions with a 2% greater incidence in the DRd arm compared to the Rd arm were pneumonia (DRd 15% vs Rd 8%), bronchitis (DRd 4% vs Rd 2%), and dehydration (DRd 2% vs Rd <1%)

Indication for REVLIMID + dexamethasone + daratumumab (DRd)
DRd is indicated for the treatment of adult patients with newly diagnosed MM who are ineligible for an autologous stem cell transplant.

Information about DRd does not appear in the REVLIMID full Prescribing Information. Please see the daratumumab full Prescribing Information and Important Safety Information at

  • AE, adverse event; auto-SCT, autologous stem cell transplantation; DRd, daratumumab + REVLIMID + dexamethasone; MM, multiple myeloma; NDMM, newly diagnosed multiple myeloma; NSCT, non-stem cell transplant; Rd, REVLIMID + dexamethasone.

References: 1. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 2. REVLIMID [package insert]. Summit, NJ: Celgene Corp.

Dosing modifications for REVLIMID may help patients with multiple myeloma stay on therapy.2*

*Until disease progression or unacceptable toxicity.